Hyperlipidemia
1-16 of 23
Erik Stroes
CME/CE Broadcast ReplayCrossing Boundaries: CETP Inhibitors and the Next Frontier in Lipid Control
0.50 creditsProf. Ulrich Laufs
Pam R. Taub, MD, FACC, FASPC
Prof. John Kastelein, Chief Scientific Officer, NewAmsterdam Pharma
Christie Ballantyne, MD
Stephen Nicholls, FRACP, FACC, FESC, FAHA
Pam R. Taub, MD, FACC, FASPC
Prof. Kausik Ray
Daniel Gaudet, MD, PhD
Pam R. Taub, MD, FACC, FASPC
Børge G. Nordestgaard, MD, DMSc
Kausik Ray, MBChB, MD, MPhil
Pam R. Taub, MD, FACC, FASPC
Kausik Ray, MBChB, MD, MPhil
Børge G. Nordestgaard, MD, DMSc
Kausik Ray, MBChB, MD, MPhil
Daniel Gaudet, MD, PhD
Børge G. Nordestgaard, MD, DMSc
Pam R. Taub, MD, FACC, FASPC
Kausik Ray, MBChB, MD, MPhil
Pam R. Taub, MD, FACC, FASPC
Kausik Ray, MBChB, MD, MPhil
MinuteCE®Setting the Bar: Guideline-Recommended Treatment in Hypertriglyceridemia
1.00 program creditBørge G. Nordestgaard, MD, DMSc
Kausik Ray, MBChB, MD, MPhil
Pam R. Taub, MD, FACC, FASPC
Kausik Ray, MBChB, MD, MPhil
Daniel Gaudet, MD, PhD
Ira J. Goldberg, MD
Kausik Ray, MBChB, MD, MPhil
Christie Ballantyne, MD
Ulrich Laufs, MD, PhD
- MinuteCE®
The remaining challenges in lowering LDL-c in patients at increased CV risk
0.75 program creditsProf. Kausik Ray
- Prev
- Next